Table 2 Investigator assessed efficacy endpoints in arm A and arm B
Endpoint | Arm A | Arm B | ||
|---|---|---|---|---|
Median (95% CI) | Median (95% CI) | HR | P value | |
Progression-free survival (months) | 6.6 (5.1–9.0) | 5.6 (3.8–6.5) | 1.80 | 0.041 |
Overall survival (months) | 20.7 (16.4–26.7) | 12.1 (5.8–20.4) | 2.01 | 0.018 |
Time to Progression (months) | 6.6 (5.1–9.0) | 5.3 (3.8–6.5) | 1.98 | 0.030 |
Time to next treatment (months) | 7.4 (6.1–10.4) | 7.0 (5.8–10.3) | 1.38 | 0.334 |
n(%);(95% CI) | n(%);(95% CI) | P value | ||
Clinical control rate | 28 (93.3) (77.6–99.2) | 21 (70.0) (52.0–83.5) | 0.020 | |
Overall response rate | 13 (43.3) (27.4–60.8) | 12 (40) (24.6–57.7) | 0.793 |